GlassScriptPhysician profile
Anna Louise Molette
NPI 1265455091
$1,664.95
in general payments reported to CMS, 2019-2025
23 companies · $19.22 in 2025
The $19.22 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $339 · 2021: $176 · 2022: $214 · 2023: $109 · 2024: $95.76 · 2025: $19.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $294.72 | 2019-2022 | |
| Abbott Laboratories | $240.76 | 2019-2024 | Eterna, Proclaim |
| Scilex Pharmaceuticals INC. | $223.77 | 2019-2021 | |
| Lundbeck LLC | $180.60 | 2022-2024 | Vyepti |
| Biodelivery Sciences International, INC. | $141.48 | 2019-2021 | |
| Pfizer INC. | $73.53 | 2019-2021 | |
| Abbvie INC. | $73.42 | 2021-2023 | |
| Medtronic, INC. | $61.68 | 2021 | |
| Averitas Pharma INC. | $42.88 | 2024-2025 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $39.98 | 2019-2023 | Dysport |
| Nevro Corp. | $36.87 | 2019 | |
| Ibsa Pharma INC. | $28.97 | 2024 | Licart, Tirosint |
| Boston Scientific Corporation | $28.33 | 2020 | |
| Collegium Pharmaceutical, INC. | $27.78 | 2019-2020 | |
| Lilly USA, LLC | $26.35 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.77 | 2019 | |
| Genzyme Corporation | $21.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.48 | 2020 | |
| Sentynl Therapeutics, INC. | $14.71 | 2019 | |
| Stimwave Technologies Incorporated | $14.70 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.97 | 2023 | Seglentis |
| Radius Health, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Louise Molette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.